OncoIndustry
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus
Agenus

BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus

Agenus, shared on LinkedIn:

“Agenus will present three-year overall survival data from the recurrent ovarian cancer cohort of the Phase 1b C-800-01 study evaluating botensilimab plus balstilimab (BOT+BAL) at the International Gynecologic Cancer Society Annual Global Meeting in Montreal.

The presentation will include analyses by platinum sensitivity status and long-term follow-up in patients with recurrent ovarian cancer.

Read the announcement.”

Don’t Miss: Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
BOT+BAL

Agenus Balstilimab BOTBAL botensilimab C-800-01 cancer OncoDaily Oncology Ovarian Cancer overall survival Phase 1b Phase 1b Clinical Trial Recurrent ovarian cancer